A shift in the phenotype of melan-A-specific CTL identifies melanoma patients with an active tumor-specific immune response

Journal of Immunology

Volumn 165, Issue 11, 2000, Pages 6644-6652

  Dunbar, P R ^a   Smith, C L ^a   Chao, D ^a   Salio, M ^a   Shepherd, D ^a   Mirza, F ^a   Lipp, M ^a   Lanzavecchia, A ^a   Sallusto, F ^a   Evans, A ^a   Russell Jones, R ^a   Harris, A L ^a   Cerundolo, V ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; HLA A2 ANTIGEN; MELAN A; MELANOMA ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CELL INFILTRATION; CELL KILLING; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; LYMPHOCYTE FUNCTION; MALE; MELANOMA; PHENOTYPE; PRIORITY JOURNAL;

EID: 0034544532     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.165.11.6644     Document Type: Article

References (42)

1. Cancer tumor antigens
2. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas
3. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor
4. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes
5. Cytolytic T lymphocyte recognition of the immunodominant HLA-A*0201-restricted Melan-A/MART-1 antigenic peptide in melanoma
6. Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1
7. Generation of tumor-specific CTLs from melanoma patients by using peripheral blood stimulated with allogeneic melanoma tumor cell lines: Fine specificity and MART-1 melanoma antigen recognition
8. Differential anti-MART-1/MelanA CTL activity in peripheral blood of HLA-A2 melanoma patients in comparison to healthy donors: Evidence of in vivo priming by tumor cells
9. Identification of epitope mimics recognized by CTL reactive to the melanoma/melanocyte-derived peptide MART-1 (27-35)
10. + melanoma patients have a memory phenotype
11. Phenotypic analysis of antigen-specific T lymphocytes
12. Direct isolation, phenotyping, and cloning of low-frequency antigen-specific cytotoxic T lymphocytes from peripheral blood
13. Ex-vivo staining of metastatic lymph nodes by class I MHC tetramers reveals high numbers of antigen-experienced tumor-specific cytotoxic T lymphocytes
14. Cutting edge: Rapid cloning of tumor-specific CTL suitable for adoptive immunotherapy of melanoma
15. An antigen-targeted approach to adoptive transfer therapy of cancer
16. High frequencies of naive Melan-A/MART-1-specific CD8((+)) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals
17. In vivo expression of natural killer cell inhibitory receptors by human melanoma-specific cytotytic T lymphocytes
18. + T cell line
19. + naive CD4 T cells
20. + T cells specific for EBV in healthy virus carriers
21. + T cells during the primary immune response to Epstein-Barr virus in vivo
22. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions
23. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients
24. Specificity of CTL interactions with peptide-MHC class I tetrameric complexes is temperature dependent
25. Serological analysis of Melan-A (MART-1), a melanocyte-specific protein homogeneously expressed in human melanomas
26. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues
27. Cytotoxic T lymphocytes recognize a fragment of influenza virus matrix protein in association with HLA-A2
28. Immediate early and early lytic cycle proteins are frequent targets of the Epstein-Barr virus-induced cytotoxic T cell response
29. Specific cytotoxic T lymphocytes recognize the immediate-early transactivator Zta of Epstein-Barr virus
30. Quantitation of HIV-1 specific cytotoxic T lymphocytes and plasma load of viral RNA
31. Analysis of the cytolytic T lymphocyte response of melanoma patients to the naturally HLA-A*0201-associated tyrosinase peptide 368-376
32. Use of fluorogenic histocompatibility leukocyte antigen-A*0201/HPV 16 E7 peptide complexes to isolate rare human cytotoxic T-lymphocytes recognizing endogenous human papillomavirus antigens
33. Immunoselection in vivo: Independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma
34. An expanded peripheral T cell population to a cytotoxic T lymphocyte (CTL)-defined, melanocyte-specific antigen in metastatic melanoma patients impacts on generation of peptide-specific CTLs but does not overcome tumor escape from immune surveillance in metastatic lesions
35. Self antigens expressed by solid tumors do not efficiently stimulate naive or activated T cells: Implications for immunotherapy
36. Antigen expressed on tumor cells fails to elicit an immune response, even in the presence of increased numbers of tumor-specific cytotoxic T lymphocyte precursors
37. Manipulation of costimulatory signals to enhance antitumor T-cell responses
38. + T cells by B7-transfected melanoma cells
39. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs
40. Consequences of cell death: Exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells
41. Molecular analysis of the HLA-A2 antigen loss by melanoma cells SK-MEL-29.1.22 and SK-MEL-29.1.29
42. 2-Microglobulin mutations. HLA class I antigen loss, and tumor progression in melanoma